Afatinib dimaleate

Afatinib dimaleate is a targeted therapy medication that is used to treat certain types of lung cancer and pancreatic cancer. It belongs to a class of drugs called kinase inhibitors, which work by blocking the action of specific proteins called kinases that promote the growth and spread of cancer cells.
Afatinib specifically targets the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2), which are proteins found on the surface of some cancer cells. By inhibiting these receptors, afatinib slows down the growth of cancer cells and may even cause them to shrink.
Afatinib dimaleate is available as a tablet and is typically prescribed for patients with advanced non-small cell lung cancer (NSCLC) that has tested positive for EGFR mutations. In such cases, afatinib may be used as a first-line treatment or after other treatments have failed. It is also used in the treatment of patients with pancreatic cancer that has tested positive for HER2 mutations.
The most common side effects of afatinib include skin rash, diarrhea, mouth sores, and changes in taste. It is important for patients to consult with their healthcare provider if they experience any of these side effects, as they may require adjustments to their treatment plan.
Afatinib dimaleate is a valuable treatment option for patients with certain types of lung and pancreatic cancer, providing a targeted approach to inhibit the growth and spread of cancer cells. By working with their healthcare team, patients can make informed decisions about whether afatinib is the right choice for their specific situation.